Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronavac vaccinees in Brazil

Cassia F. Estofolete; Cecilia A. Banho; Guilherme R.F. Campos; Beatriz C. Marques; Livia Sacchetto; Leila S. Ullmann; Fabio S. Possebon; Luana F. Machado; Juliana D. Syrio; João P. Araújo Junior; Cintia Bittar; Paula Rahal; Suzana M.A. Lobo; Helena Lage Ferreira; Nikos Vasilakis; Mauricio L. Nogueira

doi:10.3390/v13071237

Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronavac vaccinees in Brazil

Cassia F. Estofolete, Cecilia A. Banho, Guilherme R.F. Campos, Beatriz C. Marques, Livia Sacchetto, Leila S. Ullmann, Fabio S. Possebon, Luana F. Machado, Juliana D. Syrio, João P. Araújo Junior, Cintia Bittar, Paula Rahal, Suzana M.A. Lobo, Helena Lage Ferreira, Nikos Vasilakis, Mauricio L. Nogueira

Pathology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.

Original language	English (US)
Article number	1237
Journal	Viruses
Volume	13
Issue number	7
DOIs	https://doi.org/10.3390/v13071237
State	Published - Jul 2021

Keywords

COVID-19
SARS-CoV-2
Vaccine

ASJC Scopus subject areas

Infectious Diseases
Virology

Access to Document

10.3390/v13071237

Cite this

Estofolete, C. F., Banho, C. A., Campos, G. R. F., Marques, B. C., Sacchetto, L., Ullmann, L. S., Possebon, F. S., Machado, L. F., Syrio, J. D., Araújo Junior, J. P., Bittar, C., Rahal, P., Lobo, S. M. A., Ferreira, H. L., Vasilakis, N., & Nogueira, M. L. (2021). Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronavac vaccinees in Brazil. Viruses, 13(7), Article 1237. https://doi.org/10.3390/v13071237

Estofolete, CF, Banho, CA, Campos, GRF, Marques, BC, Sacchetto, L, Ullmann, LS, Possebon, FS, Machado, LF, Syrio, JD, Araújo Junior, JP, Bittar, C, Rahal, P, Lobo, SMA, Ferreira, HL, Vasilakis, N & Nogueira, ML 2021, 'Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronavac vaccinees in Brazil', Viruses, vol. 13, no. 7, 1237. https://doi.org/10.3390/v13071237

@article{77bc42e0534d4d5bbd4ba92030148c1e,

title = "Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronavac vaccinees in Brazil",

abstract = "The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.",

keywords = "COVID-19, SARS-CoV-2, Vaccine",

author = "Estofolete, {Cassia F.} and Banho, {Cecilia A.} and Campos, {Guilherme R.F.} and Marques, {Beatriz C.} and Livia Sacchetto and Ullmann, {Leila S.} and Possebon, {Fabio S.} and Machado, {Luana F.} and Syrio, {Juliana D.} and {Ara{\'u}jo Junior}, {Jo{\~a}o P.} and Cintia Bittar and Paula Rahal and Lobo, {Suzana M.A.} and Ferreira, {Helena Lage} and Nikos Vasilakis and Nogueira, {Mauricio L.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors.",

year = "2021",

month = jul,

doi = "10.3390/v13071237",

language = "English (US)",

volume = "13",

journal = "Viruses",

issn = "1999-4915",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

TY - JOUR

T1 - Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronavac vaccinees in Brazil

AU - Estofolete, Cassia F.

AU - Banho, Cecilia A.

AU - Campos, Guilherme R.F.

AU - Marques, Beatriz C.

AU - Sacchetto, Livia

AU - Ullmann, Leila S.

AU - Possebon, Fabio S.

AU - Machado, Luana F.

AU - Syrio, Juliana D.

AU - Araújo Junior, João P.

AU - Bittar, Cintia

AU - Rahal, Paula

AU - Lobo, Suzana M.A.

AU - Ferreira, Helena Lage

AU - Vasilakis, Nikos

AU - Nogueira, Mauricio L.

PY - 2021/7

Y1 - 2021/7

N2 - The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.

AB - The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.

KW - COVID-19

KW - SARS-CoV-2

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85109565185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109565185&partnerID=8YFLogxK

U2 - 10.3390/v13071237

DO - 10.3390/v13071237

M3 - Article

C2 - 34206727

AN - SCOPUS:85109565185

SN - 1999-4915

VL - 13

JO - Viruses

JF - Viruses

IS - 7

M1 - 1237

ER -

Case study of two post vaccination SARS-CoV-2 infections with P1 variants in coronavac vaccinees in Brazil

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this